Objective: To estimate the potential impact of a fixed-dose combination of sumatriptan 85mg and naproxen sodium 500mg (suma/nap) on triptan consumption in a United States managed care population of moderate-to-severe adult migraineurs. Methods: A payer-perspective pharmacy budget impact model was developed using Microsoft Excel®. Dose-specific efficacy was drawn from published meta-analyses for sumatriptan, eletriptan, rizatriptan, zolmitriptan, almotriptan, and naratriptan, and derived from published trials for suma/nap. Initial response rates at two hours, recurrence rates, and 24-hour sustained pain free rates were used to model mean triptans consumed per migraine episode. Nationally representative data for market share and quantity dispensed from commercial sources as well as prevalence data from the literature were combined with modeled triptan consumption to estimate the number of total annual prescriptions (TRx) filled. Probabilistic and scenario-based sensitivity analyses were used to assess model uncertainty. Results: In a hypothetical plan of 1,000,000 covered lives, an estimated 14,540 moderate-to-severe adult migraineurs treated with currently available triptans filled 102,206 TRx. Of the 12 triptan doses evaluated, suma/nap had the lowest mean triptan consumption per migraine episode (1.08; CI 1.06-1.09), followed by naratriptan 2.5mg (1.10; CI 1.06-1.14), eletriptan 20mg (1.14; CI 1.09-1.19), and sumatriptan 25mg (1.15; CI 1.13-1.18). After converting 8.6% of TRx share (58.3% from sumatriptan and 41.7% from other triptans according to market share) to suma/nap, migraineurs filled only 100,356 TRx, a net reduction of 1,850 prescriptions [CI 1,714-1,965]. In a second scenario converting 8.6% of TRx share (100% from sumatriptan), migraineurs filled 101,253 TRx, a net reduction of 953 prescriptions [CI 811-1,076]. Conclusion: Treating a portion of moderate-to-severe migraineurs with suma/nap reduced triptan consumption in a hypothetical nationally representative managed care plan. Further research is required to quantify the potential economic impact of this reduction once suma/nap pricing is established.